Sierra Oncology

Sierra Oncology is a late-stage drug development company based in Vancouver and California focused on the development and commercialization of Momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis including potential benefit to patients with anaemia. The product has reported positive Phase III clinical study data in second line myelofibrosis patients. The company is listed on the NASDAQ with the ticker SRRA. In April 2022 GSK announced the proposed acquisition of SRRA for $1.9bn.